Skip to main content
TipRanks
Go Ultimate75% OFF

Ultragenyx Pharmaceutical (RARE) AI Stock Analysis

1,316 Followers
RARE

Ultragenyx Pharmaceutical

(NASDAQ:RARE)

Select Model
Rating:53Neutral
Price Target:$15.50▼(-2.52% Downside)
Action:reiterated
Date:11/04/26

The score is held back primarily by weak financial performance (large losses, cash burn, and negative equity), while the latest earnings call provides meaningful offsets via major regulatory wins, nondilutive PRV cash proceeds, and a clearer 2027 profitability/cash-flow plan. Technicals are neutral and valuation is constrained by ongoing losses and no dividend.

Positive Factors
Revenue Growth and Gross MarginStrong revenue momentum combined with very high gross margins indicates improving commercial traction and attractive product economics. If sustained, this profile can provide increasing resources to fund launches, support selective pipeline investment, and strengthen the company’s ability to approach profitability.
Negative Factors
Persistent Losses and Cash BurnLarge negative operating and free cash flow show that the business has not yet converted commercial growth into internal funding. Continued cash consumption can constrain investment choices and increase dependence on successful launches, cost reductions, or additional capital before profitability is achieved.

Ultragenyx Pharmaceutical Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down revenue across different regions, revealing where Ultragenyx Pharmaceutical is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.

$0.00$50.00M$100.00M$150.00M$200.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

North America remains the primary revenue engine but shows sharp quarter-to-quarter swings driven by seasonality and order timing; meanwhile Latin America, Europe and a nascent Japan business are growing fast—reflecting Crysvita and Evkeeza geographic rollouts and rising patient counts—which meaningfully diversifies the base. Management’s record-quarter claim is supported, but sustaining momentum and reaching the 2027 profitability plan still depends on continued commercial traction plus binary near‑term FDA outcomes (DTX‑401/UX‑111) and potential PRV monetization as backstop.

Data provided by:The Fly

Ultragenyx Pharmaceutical (RARE) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%RARE-50.09%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.62B
Dividend Yield
―
Average Volume (3M)
4.60M
Price to Earnings (P/E)
-3.1
Beta (1Y)
1.47
Revenue Growth
15.76%
EPS Growth
12.63%
Country
US
Employees
1,371
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Ultragenyx Pharmaceutical Business Overview & Revenue Model

Company Description

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international...

How the Company Makes Money

Ultragenyx makes money primarily by selling its commercial rare-disease medicines and recording product revenue from those sales. The company’s key revenue streams are: (1) Product sales of its approved therapies, where revenue is generated through d...

Ultragenyx Pharmaceutical Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:-4.39%|Next Earnings Date:Feb 18, 2027
Earnings Call SentimentNeutral

The call had substantial positive developments, including two first-ever gene therapy approvals, strong demand and launch preparation, growth across established products, approximately $350 million in nondilutive proceeds, and reaffirmed 2027 profitability expectations. These were balanced by the GTX-102 Phase 3 failure, termination of UX701, a roughly 20% workforce reduction, restructuring charges, and uncertainty around the setrusumab regulatory path. Overall sentiment was mixed and balanced.

Positive Updates

Two First-Ever Gene Therapy Approvals
The FDA approved GENGLYCOS in August for Glycogen Storage Disease Type Ia and FAYUVI in September for Sanfilippo syndrome Type A. These approvals brought Ultragenyx to six approved medicines and its first two gene therapies.

Negative Updates

GTX-102 Phase 3 Efficacy Failure
The GTX-102 Phase 3 study in Angelman syndrome failed to prove efficacy, contrary to the company's expectations after compelling Phase 2 data. Management said variability in the control group across multiple endpoints prevented a distinct separation in a one-year randomized trial, and the clinical program is being discontinued.

Company Guidance

Ultragenyx reaffirmed 2026 total revenue guidance of $730 million to $760 million, excluding revenue from FAYUVI and GENGLYCOS, including CRYSVITA revenue of $500 million to $520 million and DOJOLVI revenue of $100 million to $110 million, and expects combined R&D and SG&A expenses to be flat to down low single digits versus 2025, including $30 million in severance and other nonrecurring restructuring charges from the first half of the year and approximately $25 million expected in the fourth quarter; for 2027, it expects to provide full year revenue guidance early in the new year, R&D expenses of less than $350 million, a reduction of more than 50% from 2025 levels, SG&A expenses of less than $375 million, an increase of up to 7% from 2025 levels, headcount reduced by approximately 20% to a revised workforce of approximately 1,000 employees, full year GAAP net income profitability and positive cash flow from operating activities, with net proceeds from the sale of two PRVs totaling approximately $350 million.

Ultragenyx Pharmaceutical Financial Statement Overview

Summary

Strong revenue momentum and high gross margins, but financial quality remains weak: deep ongoing losses, heavy operating/free-cash-flow burn, and negative equity that increases financing and dilution risk. Balance sheet uncertainty around debt levels further elevates risk despite improving commercial execution.

Income Statement

28Negative

Balance Sheet

18Very Negative

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue730.00M673.00M560.23M434.25M363.33M351.41M
Gross Profit605.00M564.00M483.50M389.04M335.01M335.40M
EBITDA-417.21M-474.00M-469.00M-516.45M-640.49M-410.32M
Net Income-524.00M-575.00M-569.18M-606.64M-707.42M-454.02M
Balance Sheet
Total Assets1.19B1.53B1.50B1.49B1.55B1.52B
Cash, Cash Equivalents and Short-Term Investments266.00M693.00M610.02M577.21M747.76M740.20M
Total Debt1.19B1.28B40.34M43.17M31.59M41.97M
Total Liabilities1.56B1.60B1.24B1.22B1.19B599.84M
Stockholders Equity-376.00M-80.00M255.30M275.41M352.49M922.56M
Cash Flow
Free Cash Flow-441.77M-472.00M-421.68M-521.57M-526.59M-411.79M
Operating Cash Flow-436.83M-466.00M-414.19M-474.81M-380.46M-338.69M
Investing Cash Flow-19.25M236.00M-17.77M168.00M-291.65M-195.37M
Financing Cash Flow407.19M478.00M399.24M388.14M501.21M118.55M

Ultragenyx Pharmaceutical Technical Analysis

Technical Analysis SentimentNegative
Last Price15.90

Price Trends

50DMA15.30Positive
100DMA21.51Negative
200DMA22.49Negative

Market Momentum

MACD0.01Negative
RSI47.77Neutral
STOCH37.78Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RARE, the sentiment is Negative. The current price of 15.90 is below the 20-day moving average (MA) of 16.25, above the 50-day MA of 15.30, and below the 200-day MA of 22.49, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 47.77 is Neutral, neither overbought nor oversold. The STOCH value of 37.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RARE.

Ultragenyx Pharmaceutical Risk Analysis

Ultragenyx Pharmaceutical disclosed 61 risk factors in its most recent earnings report. Ultragenyx Pharmaceutical reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.We may experience difficulties, delays or unexpected costs and not achieve anticipated benefits and savings from our recently initiated strategic restructuring plan.Q4, 2025
2.Our products are subject to regulatory scrutiny, even after approval.Q4, 2025
3.Regulatory standards are subject to change over time, making it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints.Q4, 2025

Ultragenyx Pharmaceutical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RARE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IRONIRON68Neutral$3.49B-12.21-36.33%――-18.27%
TARSTARS54Neutral$3.88B-5.14-245.72%―86.34%-654.07%
RARERARE53Neutral$1.62B-3.08213.22%―15.76%12.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TVTXTVTX48Neutral$4.77B-32.00-186.46%―49.38%-58.47%
XENEXENE46Neutral$3.86B-8.35-39.80%―-100.00%-21.09%
MLYSMLYS42Neutral$1.29B-3.38-63.26%――-47.55%

* Healthcare Sector Average

Performance Comparison

-50%0%50%RARETVTXXENEIRONTARSMLYSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RARE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RAREUltragenyx Pharmaceutical, Inc.15.90-16.93-51.57%
TVTXTravere Therapeutics, Inc.49.7013.7038.06%
XENEXenon Pharmaceuticals39.26-1.35-3.32%
IRONDisc Medicine, Inc.76.59-13.15-14.65%
TARSTarsus Pharmaceuticals, Inc.78.681.712.22%
MLYSMineralys Therapeutics, Inc.14.53-28.86-66.51%

Ultragenyx Pharmaceutical Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A TransactionsProduct-Related Announcements

Ultragenyx Announces Workforce Reduction and Strategic Restructuring

Negative
Nov 3, 2026

On October 30, 2026, Ultragenyx completed the sale of its GENGLYCOS-related Rare Pediatric Disease Priority Review Voucher for $210 million. The FDA had awarded the voucher on August 19 after approving GENGLYCOS for patients aged eight and older with...

Business Operations and StrategyLegal Proceedings

Ultragenyx, Baylor Reach Settlement on DOJOLVI Patents

Neutral
Oct 19, 2026

On October 19, 2026, Ultragenyx Pharmaceutical Inc. and Baylor Research Institute reached a settlement with Navinta LLC, resolving patent litigation over patents covering Ultragenyx’s DOJOLVI triheptanoin oral liquid. The dispute stemmed from Navinta...

Business Operations and StrategyPrivate Placements and Financing

Ultragenyx Sells FDA Priority Review Voucher for Cash

Positive
Oct 14, 2026

On October 8, 2026, Ultragenyx Pharmaceutical Inc. agreed to sell a Rare Pediatric Disease Priority Review Voucher that it had received from the U.S. Food and Drug Administration on September 17, 2026, following approval of FAYUVI (UX111) for treatin...

Business Operations and StrategyPrivate Placements and Financing

Ultragenyx Monetizes FDA Priority Review Voucher Asset

Positive
Oct 7, 2026

On October 6, 2026, Ultragenyx Pharmaceutical Inc. entered into an asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher that it received from the U.S. Food and Drug Administration on August 19, 2026, following approval of...

Business Operations and StrategyProduct-Related Announcements

Ultragenyx wins FDA approval for FAYUVI gene therapy

Positive
Sep 17, 2026

On September 17, 2026, Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration granted full approval to FAYUVI, also known as UX111, for treating pediatric patients with mucopolysaccharidosis type IIIA, or Sanfilippo syndr...

Business Operations and Strategy

Ultragenyx pivots strategy after Aspire Phase 3 setback

Negative
Sep 2, 2026

On September 2, 2026, Ultragenyx reported Phase 3 results from the Aspire study of apazunersen (GTX-102) in Angelman syndrome, showing the trial failed to meet its primary cognitive endpoint and key secondary multidomain responder endpoint. With no e...

Business Operations and StrategyProduct-Related Announcements

Ultragenyx Wins FDA Accelerated Approval for GENGLYCOS

Positive
Aug 19, 2026

On August 19, 2026, Ultragenyx announced that the U.S. Food and Drug Administration granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, for adult and pediatric patients eight years and older with glycog...

Business Operations and StrategyLegal Proceedings

Ultragenyx Settles DOJOLVI Patent Dispute with Esjay

Positive
Aug 11, 2026

On August 7, 2026, Ultragenyx Pharmaceutical and Baylor Research Institute reached a settlement with Esjay Pharma resolving U.S. patent litigation over DOJOLVI, after Esjay filed an Abbreviated New Drug Application to market a generic version. Under...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026